Debra Patt, President of the Community Oncology Alliance, Executive Vice President Policy and Strategy at Texas Oncology, shared a post on LinkedIn:
“Excited about our leaders in Advanced therapy at Texas Oncology like Dr. Ram Kamble continuing to advance progress in patients with advanced cancer requiring cellular therapy. Through the leadership of Eve Stahl, Molly Lawson and Houston Holmes we continue to live the mission at Texas Oncology and allow patients to have access to the most cutting edge cancer care close to home.”
Title: Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma
Authors: Nausheen Ahmed, Alaa Ali, Soyoung Kim, Temitope Oloyede, Matthew Bye, Lohith Gowda, Rammurti T Kamble, Abu-Sayeef Mirza, Kalyan V Nadiminti, Priyanka A Pophali, Carlos Rodriguez-Bonilla, Alex Sieg, Christopher Strouse, Muhammad Bilal Abid, Aimaz Afrough, Mahmoud Aljurf, Amer M Beitinjaneh, Saurabh Chhabra, Michelle Choe, Talal Hilal, Madiha Iqbal, Tania Jain, Mohamed A Kharfan-Dabaja, Dipenkumar Modi, Guillermo Orti, Attaphol Pawarode, Uttam Rao, Peter A Riedell, Ayman Saad, Sachiko Seo, Anna Sureda Balari, John L Wagner, Kitsada Wudhikarn, Cameron J Turtle, Christine L Phillips, Marcelo C Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop
Other articles featuring Debra Patt on OncoDaily.